Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05533775 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
A Phase 1 study of Mature B-Cell Non-Hodgkin Lymphoma, sponsored by Hoffmann-La Roche.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 65
- Enrollment target
- 20
- Study locations
NCT05533775 is a Phase 1 study of Mature B-Cell Non-Hodgkin Lymphoma that is actively recruiting participants, run by Hoffmann-La Roche. The registered enrollment target is 65 participants. The trial reports 20 study locations across 12 states.
The verdict
NCT05533775, a Phase 1 study of Mature B-Cell Non-Hodgkin Lymphoma, is actively recruiting participants, sponsored by Hoffmann-La Roche.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 65 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and efficacy of glofitamab, as monotherapy and in combination with a standard chemoimmunotherapy regimen: rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) in pediatric and young adult participants with relapsed and refractory (R/R) mature B-cell non-Hodgkin lymphoma (B-NHL).
Conditions Studied
Interventions
- DRUG Obinutuzumab
- DRUG Glofitamab
- DRUG Carboplatin
- DRUG Rituximab
- DRUG Ifosfamide
Study Locations (20)
Other
- Sun Yet-sen University Cancer Center - Guangzhou
- Fakultni nemocnice v Motole;Klinika detske hematologie a onkologie - Prague
- Rigshospitalet - København Ø
- Hôpital Pellegrin - Bordeaux
- Gustave Roussy - Villejuif
- Universitaetsklinikum Muenster - Münster
California
- UCSF Benioff Children's Hospital Oakland - Oakland
- Kaiser Permanente Oakland Medical Center - Oakland
- Kaiser Permanente - Roseville - Roseville
- Kaiser Permanente - Santa Clara - Santa Clara
Alabama
- Children's Hospital of Alabama - Birmingham
Maryland
- Johns Hopkins University - Baltimore
Massachusetts
- Dana-Farber Cancer Institute - Boston
Missouri
- Childrens Mercy Hosp & Clinics - Kansas City
New York
- MSKCC - New York
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2022-11-16 |
| Est. Completion | 2032-11-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05533775
The ClinicalTrials.gov registry entry for NCT05533775 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Mature B-Cell Non-Hodgkin Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Obinutuzumab is the first listed.
NCT05533775 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Other, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT05533775 about?
NCT05533775 is a clinical study titled "A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma". The purpose of this study is to evaluate the safety and efficacy of glofitamab, as monotherapy and in combination with a standard chemoimmunotherapy regimen: rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) in pediatric and young adult participants with relapsed and refractory (R/R) mature ...
What is the current status of trial NCT05533775?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 65 participants. The study started on 2022-11-16. Estimated completion is 2032-11-30.
What conditions does trial NCT05533775 study?
This clinical trial studies the following conditions: Mature B-Cell Non-Hodgkin Lymphoma.
What interventions are being tested in trial NCT05533775?
The interventions under investigation include: Obinutuzumab (DRUG), Glofitamab (DRUG), Carboplatin (DRUG), Rituximab (DRUG), Ifosfamide (DRUG).
Who is sponsoring clinical trial NCT05533775?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05533775 being conducted?
This trial has 20 study locations across Alabama, California, Maryland, Massachusetts, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.